IS BCG ALONE ENOUGH?

Your patients may need more than Bacillus Calmette-Guérin (BCG) treatment to address the risk of early recurrence and eventual progression1,2

Several factors can raise the risk of RECURRENCE and PROGRESSION1,3-7
Image depicting multiple kinds of tumors of various size and shape protruding into the 3 layers of the bladder. Image depicting multiple kinds of tumors of various size and shape protruding into the 3 layers of the bladder.
 
Image depicting multiple kinds of tumors of various size and shape protruding into the 3 layers of the bladder.
Image depicting 1 in 3 silhouetted figures shaded in1 in 3
patients will experience EARLY RECURRENCE within 1 year3-5,8,9

Up to one-third of HR-NMIBC cases with higher-risk features* will recur early, within 1 year.

*Based on patients with HG T1, HG Ta, concomitant CIS, and multifocal disease.

Image depicting 1 in 2 silhouetted figures shaded in1 in 2
patients will experience PROGRESSION within 5 years6

Up to half of HR-NMIBC cases with select higher-risk features† will progress within 5 years.

†Based on T1 with multifocal CIS.

What Options Remain IF BCG Fails?

BCG failure severely limits treatment options outside of clinical trials1,2,5,10

Guidelines recommend:
Icon depicting intravesical chemotherapyIntravesical chemotherapy
OR
Icon depicting radical cystectomyRadical cystectomy

Some bladder-sparing therapies are available for BCG-unresponsive HR-NMIBC with higher-risk features but are limited to a fraction of patients.1,2,5,10

Radical cystectomy: A life-altering treatment1,2,5,10-12

While radical cystectomy (RC) is recommended by major current guidelines, it seriously affects patients’ quality of life.

decorativeIrreversible physical effects
decorativeLasting emotional consequences
decorativeDiminished sexual health and function
LOCAL + SYSTEMIC THERAPIES

BCG-naïve patients with HR-NMIBC with higher-risk features need options that work with and go beyond localized BCG therapy1,2

AstraZeneca is committed to improving the lives of patients by advancing the science and exploring the potential to COMBINE LOCAL and SYSTEMIC APPROACHES.
Icon depicting local and systemic approaches to the treatment of HR-NMIBC